MT-3724

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameMT-3724

Drug Alias NameMT-3724

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-chain FV antibody fragment (scFv)Biologics > Protein drugs > Toxin

Mechanisms of ActionAnti-CD20

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsHematologic NeoplasmsLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesUkraine +[10]

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMolecular Partners Ag

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMolecular Templates Inc

Active IndicationsN/A

Inactive IndicationsHematologic NeoplasmsLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[5]

Other Information

ATC CodeN/A